Chiome Bioscience is a biotech company established in 2005. Since its inception, we have been engaged in the development of antibody-related technologies, and the research and development of therapeutic antibodies.
Antibodies are an important modality in marketed drugs and will continue to play a significant role in the drug discovery scene. However, there is also a need to evolve by combining other technologies such as ADC and multi-specific antibodies. We, Chiome Bioscience, are also responding to these needs with our technology.

In addition, we are not limited to exploratory antibody drug research, but have also pursued clinical development of our own programmes, and have accumulated a wide range of knowledge, experience and technology ("Intelligence") from exploratory research to clinical development in antibody drug discovery. We believe that our "Intelligence" is not only the foundation for promoting in-house drug discovery, but also contributes to strengthening Japan's drug discovery capabilities through the drug discovery ecosystem.

Our efforts are focused on bringing clinical benefit to patients suffering from diseases and addressing unmet medical needs. We invite all stakeholders to support Chiome Bioscience as we embark on a path of antibody drug discovery based on our "intelligence".